Dividends & Buybacks ·
Rallybio approves one-for-two reverse stock split effective Nov. 20 ahead of merger with Avenzo
RLYBRallybio Corp
Rallybio Corporation's Board of Directors, with mutual agreement from Avenzo Therapeutics, approved a one-for-two reverse stock split to be implemented in connection with their pending merger. The split is expected to become effective at 12:01 a.m. Eastern Time on November 20, 2026, prior to the anticipated closing of the transaction. This action reduces the number of issued and outstanding common shares from approximately 5.6 million to 2.8 million. Following Nasdaq approval and merger completion, Rallybio will change its name to Avenzo Therapeutics and trade under the symbol "AVZO" on the Nasdaq Capital Market. Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases.